We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Highly Sensitive Blood Test to Enable Earlier Detection of Common Deadly Cancers

By LabMedica International staff writers
Posted on 09 Nov 2023
Print article
Image: The new blood test could offer earlier detection of common deadly cancers (Photo courtesy of 123RF)
Image: The new blood test could offer earlier detection of common deadly cancers (Photo courtesy of 123RF)

Cancer often becomes fatal by stealthily progressing without causing any symptoms, which results in a delay in diagnosis until it’s too late for treatment. Ovarian and gastroesophageal cancers are notorious for such silent advancement, which usually means they are not detected until they have reached a late stage. In an exciting development, researchers have developed a blood test that is remarkably sensitive and capable of identifying a specific protein indicative of cancer cells, potentially allowing for earlier detection. This test stands out from others, as it doesn't focus on just one type of cancer, isn't prohibitively expensive, and doesn't require invasive procedures to obtain tissue samples. Instead, it’s a cost-effective, comprehensive cancer screening tool that can detect a protein marker called LINE-1-ORF1p from a small blood sample within less than two hours.

In the burgeoning field of cancer biomarker detection, many biomarkers have been identified, yet they often come with significant limitations. Some necessitate surgical biopsy procedures, while others aren’t utilized until after symptoms appear, which may be too late to make a meaningful impact. Additionally, many biomarkers are proteins that naturally occur in humans and vary from one individual to another, complicating the interpretation of results. Moreover, most are specific to one type of cancer, limiting their usefulness. However, the discovery of LINE-1 ORF1p, a biomarker identified around ten years ago, has raised hope. LINE-1 is a repetitive element in human DNA that can duplicate itself and insert the copy elsewhere in the genome, and ORF1p is a protein it produces, which is found at high levels in cancer cells right from the beginning of the disease. Researchers have been on the quest for a test sensitive and precise enough to detect ORF1p early on. Detecting this biomarker in patients before the cancer spreads could be life-saving.

An international team of researchers, including from The Rockefeller University (New York, NY, USA), have developed an assay that is both fast as well as inexpensive, and capable of detecting ORF1p in plasma— which comprises over half of the content of human blood. By using a single-molecule-based detection technology known as Simoa that utilizes custom-designed nanobodies—small antibodies from llamas—this test can accurately latch onto and identify the ORF1p protein. It has been effective in identifying ORF1p in blood samples from patients with various cancers such as ovarian, gastroesophageal, and colorectal cancer, all for less than USD 3 and with quick turnaround. When the team analyzed blood plasma from 400 healthy individuals from a biobank, they found that 97–99% had no detectable levels of ORF1p. Interestingly, of the five individuals who did show detectable levels, one person was later diagnosed with advanced prostate cancer.

The test also shows promise as a way to monitor a patient’s response to cancer treatments. For instance, if a treatment is working, the levels of ORF1p should decline. This was observed in a group of patients with gastroesophageal cancer, where those responding to treatment showed a decrease in ORF1p to levels that went undetected by the test. Therefore, tracking this protein might one day be a regular part of health care. The study not only showcases the capabilities of the assay but also highlights the vast potential of nanobodies, which are studied through interactomics—a field dedicated to understanding how the myriad of components within a cell, especially proteins and nucleic acids, interact to form complexes that govern cell behavior and can lead to diseases when these interactions go awry.

“The assay has groundbreaking potential as an early diagnostic test for lethal cancers,” said Michael P. Rout, head of the Rockefeller lab. “These kinds of ultrasensitive detection instruments are poised to improve patient outcomes in transformative ways.”

Related Links:
The Rockefeller University

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
All-in-one Molecular Diagnosis System
Panall 8000

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.